Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
IPO Year: 2016
Exchange: NASDAQ
Website: clearsidebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2024 | $6.00 | Buy | Chardan Capital Markets |
| 6/25/2024 | $5.00 | Outperform | Oppenheimer |
| 3/11/2022 | $11.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $19.00 → $9.00 | Outperform | Wedbush |
| 7/29/2021 | $10.00 | Buy | HC Wainwright & Co. |